InvAntigen
Therapeutics
Illuminating the Dark Proteome for Cancer Immunotherapy
Precision Antigens Empower Next- Generation Cancer Immunotherapy
InvAntigen Therapeutics is advancing the next frontier in cancer treatment by transforming how tumor antigens are discovered, confirmed, and utilized. Our mission is to expand the reach and effectiveness of cancer immunotherapy by enabling direct identification of antigenic peptides from patient tissue. Using our proprietary proteomic platform, we uncover tumor-associated and tumor-specific antigens from formalin-fixed, paraffin-embedded (FFPE) samples — the standard pathology resource in clinical oncology. This proprietary technology provides a critical foundation for treatment with tumor antigen-targeted immunotherapeutics including off-the-shelf and personalized cancer vaccines, dramatically improving targeting accuracy and therapeutic efficacy.
Born from decades of leadership at the NIH and biotech industrial innovation, InvAntigen bridges the gap between complex proteomics and clinical application. Our scientific team has pioneered landmark technologies in multi-omics, molecular pathology and cancer diagnostics, and now apply their expertise to redefine how immunotherapy is designed. With a unique focus on FFPE patient tissue we enable and expand precision immunotherapy at a scale and depth previously unattainable.
InvAntigen Therapeutics Technology Platform
Current state-of-the-art technology is limited in identifying antigenic peptides for optimal cancer immunotherapy. InvAntigen Therapeutics has addressed this obstacle by developing a proprietary proteomic platform for identifying, confirming, and prioritizing tumor-associated and tumor-specific antigenic peptides directly from formalin fixed paraffin embedded (FFPE) cancer patient tissue. The platform identifies cancer antigenic peptides from clinical patient tissue, both canonical (from biomarker targets, mutated exons and viral sequences) and noncanonical (from ncORFs, proteasome splicing, and dysregulated RNA splicing).
Revolutionizing Precision Cancer Immunotherapy
Team
The scientific team at InvAntigen Therapeutics are pioneers in cancer research, molecular pathology, multi-omics, and clinical diagnostics, with decades of collective experience translating biomedical innovations into practical tools for cancer therapy. With deep roots in the NIH and biotech industry, they have developed groundbreaking technologies for analyzing FFPE patient tissue—laying the foundation for InvAntigen’s transformative approach to cancer immunotherapy.
David Krizman PhD
Founder
Dr. Krizman is a biomedical scientist known for creating and commercializing genomic, proteomic, and histopathology technologies. At the National Human Genome Research Institute and National Cancer Institute (NIH), he developed methods to identify genes and their expression in FFPE cancer tissue. He co-directed NCI’s Cancer Genome Anatomy Project (CGAP), co-founded Expression Pathology Inc, and established a commercial clinical diagnostic laboratory for proteomic analysis of cancer patient tissue. In addition, Dr. Krizman has served DARPA in the past and currently serves the US Department of Defense in various capacities. At InvAntigen, his focus is to revolutionize cancer immunotherapy by targeting the “dark proteome” accessed directly from FFPE cancer patient tissue.
Michael Emmert-Buck MD/PhD
Scientific Advisor
Dr. Emmert-Buck, a physician scientist with over 20 years at the National Cancer Institute, has published >200 scientific publications and book chapters. He co-invented Laser Capture Microdissection and co-directed NCI’s Cancer Genome Anatomy Project (CGAP). His career reflects a focus on innovative approaches to analysis of FFPE patient tissue for clinical diagnostics and therapeutics. With extensive entrepreneurial experience as co-founder of Expression Pathology Inc he provides a significant contribution to InvAntigen Therapeutics in reimagining how cancer antigens are identified directly from FFPE cancer patient tissue and utilized for immunotherapy intervention.
Marlene Darfler
Senior Scientist
Marlene Darfler is a biotechnology expert with vast experience in molecular biology product development for cancer diagnostics. As co-founder of Expression Pathology Inc she co-invented proteomic profiling technologies of FFPE patient tissue by mass spectrometry and was instrumental in establishing a CLIA-certified, CAP-accredited clinical diagnostic laboratory for protein quantitation of FFPE patient tissue for optimal cancer therapeutic decisions. She brings extensive expertise to InvAntigen Therapeutics for detecting cancer antigenic peptides directly from FFPE patient tissue for immunotherapy targeting.
Let’s Connect
InvAntigen Therapeutics has developed proprietary innovative solutions for discovering, confirming, and prioritizing cancer antigens and neoantigens directly from FFPE cancer patient tissue—advancing precision approaches to cancer immunotherapy. We are actively seeking partnerships with organizations focused on immuno-therapeutic development to expand the impact and reach of next-generation cancer vaccines and immunotherapeutics.
To explore collaboration opportunities or request our whitepaper, please reach out through the contact link or email us directly.
Contact Information:
Email: admin@invantigentx.com
We look forward to connecting with partners who share our mission to transform cancer care.
